Posted by Michael Wonder on 02 Aug 2019
Mylan and Biocon launch first trastuzumab biosimilar Ogivri in Australia
1 August 2019 - Biocon and Mylan today announced the launch in Australia of Ogivri (trastuzumab), a biosimilar to Herceptin (trastuzumab), for the treatment of HER2-overexpressing breast cancer and metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma).
Ogivri is the first trastuzumab biosimilar approved and launched in Australia and available on the Pharmaceutical Benefits Scheme.
Biosimilars generate savings that help manage the growing costs of Australia’s health care system, particularly the PBS. They enable greater patients access to necessary treatments and free up funding for the listing of the latest treatments.
